{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T04:21:47Z","timestamp":1790050907871,"version":"4.0.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,6,27]],"date-time":"2023-06-27T00:00:00Z","timestamp":1687824000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,6,27]],"date-time":"2023-06-27T00:00:00Z","timestamp":1687824000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1007\/s40265-023-01911-7","type":"journal-article","created":{"date-parts":[[2023,6,27]],"date-time":"2023-06-27T09:02:07Z","timestamp":1687856527000},"page":"1125-1130","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Efbemalenograstim Alfa: First Approval"],"prefix":"10.1007","volume":"83","author":[{"given":"Hannah A.","family":"Blair","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,27]]},"reference":[{"key":"1911_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102427","volume":"109","author":"DW Blayney","year":"2022","unstructured":"Blayney DW, Schwartzberg L. Chemotherapy-induced neutropenia and emerging agents for prevention and treatment: a review. Cancer Treat Rev. 2022;109: 102427.","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"1911_CR2","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1080\/16078454.2021.1965725","volume":"26","author":"A Theyab","year":"2021","unstructured":"Theyab A, Algahtani M, Alsharif KF, et al. New insight into the mechanism of granulocyte colony-stimulating factor (G-CSF) that induces the mobilization of neutrophils. Hematology. 2021;26(1):628\u201336.","journal-title":"Hematology"},{"issue":"3","key":"1911_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0091990","volume":"9","author":"GN Cox","year":"2014","unstructured":"Cox GN, Chlipala EA, Smith DJ, et al. Hematopoietic properties of granulocyte colony-stimulating factor\/immunoglobulin (G-CSF\/IgG-Fc) fusion proteins in normal and neutropenic rodents. PLoS ONE. 2014;9(3):1\u20138.","journal-title":"PLoS ONE"},{"issue":"4","key":"1911_CR4","first-page":"875","volume":"57","author":"X-d Wang","year":"2022","unstructured":"Wang X-d, Liu J-h, Chen K-n, et al. Recent advances on long-acting recombinant human granulocyte colony-stimulating factor. Acta Pharmaceutica Sinica. 2022;57(4):875\u201383.","journal-title":"Acta Pharmaceutica Sinica."},{"key":"1911_CR5","unstructured":"Evive Biotech. Efbemalenograstim alfa injection: Chinese prescribing information. Beijing: Evive Biotech; 2023."},{"key":"1911_CR6","unstructured":"Evive Biotech. Evive Biotech meets primary and secondary endpoints in global phase III clinical trial for their novel chemotherapy induced neutropenia treatment [media release]. 7 Jul 2020. http:\/\/www.evivebiotech.com."},{"key":"1911_CR7","unstructured":"Evive Biotech. Evive Biotech and Sino Biopharm subsidiary announce strategic collaboration to commercialize F-627 in China [media release]. 30 August 2021. http:\/\/www.evivebiotech.com."},{"key":"1911_CR8","unstructured":"APOGEPHA. Evive Biotech and APOGEPHA announce collaboration to market efbemalenograstim alfa (F-627) in Germany and Switzerland [media release]. 4 Jul 2022. https:\/\/www.apogepha.de\/."},{"key":"1911_CR9","unstructured":"Acrotech Biopharma. Evive enters license agreement with Acrotech Biopharma to commercialize Ryzneuta\u2122 in the United States [media release]. 22 Nov 2022. https:\/\/acrotechbiopharma.com\/."},{"issue":"Suppl. 1","key":"1911_CR10","doi-asserted-by":"publisher","first-page":"4290","DOI":"10.1182\/blood-2021-145760","volume":"138","author":"J Glaspy","year":"2021","unstructured":"Glaspy J, Daley W, Bondarenko I, et al. A phase III, randomized, multi-center, open-label, fixed dose, Neulasta active-controlled clinical trial of F-627, a novel G-CSF, in women with breast cancer receiving myelotoxic chemotherapy [abstract]. Blood. 2021;138(Suppl. 1):4290\u20131.","journal-title":"Blood"},{"issue":"21","key":"1911_CR11","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1182\/blood.V116.21.1485.1485","volume":"116","author":"ZT Hu","year":"2010","unstructured":"Hu ZT, Huang ZH, Cen XB, et al. F-627, a G-CSF dimer, stimulated a more rapid neutrophil recovery in cyclophosphamide-treated monkeys compared to monomer Rhg-CSFs. Blood. 2010;116(21):1485.","journal-title":"Blood"},{"issue":"21","key":"1911_CR12","doi-asserted-by":"publisher","first-page":"4722","DOI":"10.1182\/blood.V116.21.4722.4722","volume":"116","author":"XQ Yan","year":"2010","unstructured":"Yan XQ, Hodsman PG, Huang ZH, et al. An open-label, single ascending dose phase I study of F-627, a G-CSF dimer, in healthy male subjects [abstract]. Blood. 2010;116(21):4722.","journal-title":"Blood"},{"issue":"23","key":"1911_CR13","doi-asserted-by":"publisher","first-page":"4601","DOI":"10.1182\/blood.V126.23.4601.4601","volume":"126","author":"JN Cao","year":"2015","unstructured":"Cao JN, Yuan ZY, Huang C, et al. Phase Ib studies of benegrastim in Chinese women with breast cancer receiving myelotoxic chemotherapy [abstract]. Blood. 2015;126(23):4601.","journal-title":"Blood"},{"issue":"1","key":"1911_CR14","first-page":"238","volume":"45","author":"H Link","year":"2022","unstructured":"Link H, Glaspy J, Daley W, et al. A novel, long-acting G-CSF fusion protein without PEGylation in women with breast cancer receiving myelotoxic chemotherapy\u2014results of a pivotal randomized, controlled clinical trial [abstract no 1036]. Oncol Res Treat. 2022;45(1):238.","journal-title":"Oncol Res Treat."},{"key":"1911_CR15","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1158\/1538-7445.SABCS21-P5-16-14","volume":"82","author":"W Daley","year":"2022","unstructured":"Daley W, Shao Z, Zhang Q, et al. A randomized, multicenter phase III study of once-per-cycle administration of efbemalenograstim alfa (F-627), a novel long-acting dimeric rhG-CSF, for prophylaxis of chemotherapy-induced neutropenia in patients with breast cancer [abstract no P5\u201316-14]. Cancer Res. 2022;82:4.","journal-title":"Cancer Res"},{"key":"1911_CR16","unstructured":"Glaspy J, Tang T, Rutty D, et al. A phase III, randomized, multi-centre, double-blind, placebo-controlled clinical trial of F-627 in women with breast cancer receiving myelotoxic chemotherapy [abstract]. In: 41st Annual San Antonio Breast Cancer Symposium. 2018."},{"issue":"21","key":"1911_CR17","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1182\/blood.V124.21.1584.1584","volume":"124","author":"J Glaspy","year":"2014","unstructured":"Glaspy J, Tang T, Rutty D, et al. A phase II, randomized, multi-centre, open-label, active-controlled, dose-finding trial of F-627 (benefilgrastim) in women with breast cancer receiving myelotoxic chemotherapy [abstract]. Blood. 2014;124(21):1584.","journal-title":"Blood"},{"key":"1911_CR18","unstructured":"Evive Biotech. 2015. Efbemalenograstim alfa study GC-627-02 (data on file)."},{"key":"1911_CR19","unstructured":"China Daily. Ryzneuta approved for use in China [media release]. 10 May 2023. https:\/\/www.chinadaily.com.cn\/a\/202305\/10\/WS645b3f0aa310b6054fad22c3.html."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-023-01911-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-023-01911-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-023-01911-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T15:23:18Z","timestamp":1689952998000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-023-01911-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,27]]},"references-count":19,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["1911"],"URL":"https:\/\/doi.org\/10.1007\/s40265-023-01911-7","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,27]]},"assertion":[{"value":"27 June 2023","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Hannah Blair is a salaried employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}